Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Active Biotech has presented encouraging results from the preclinical studies of the Tumor Targeted Superantigens technology, which was studied and evaluated in combination with a standard chemotherapeutic agent, Taxotere.
Subscribe to our email newsletter
The combination of Tumor Targeted Superantigens (TTS) and Taxotere significantly improved anti-tumor activity compared to the respective mono therapy. Furthermore, combining TTS and Taxotere synergistically prolonged long-term survival in tumor bearing mice.
In conclusion, the results of the study demonstrate that TTS therapy is suitable for combination treatment agents such as Taxotere, and suggest a significant potential for such a combination in human cancer therapy.
The drug candidate Anyara, using the TTS technology, is currently in pivotal Phase II/III clinical trials for renal cell cancer and an interim analysis is planned for mid 2008.